NEUE · As filed with the SEC

NeueHealth cash flow statement, by quarter

The statement as NeueHealth presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Condensed Consolidated Statements of Cash Flows · USD thousands

USD thousands	Q2 2025^† 3 months ended Jun 30, 2025	Q1 2025 3 months ended Mar 31, 2025	Q4 2024^† 3 months ended Dec 31, 2024	Q3 2024^† 3 months ended Sep 30, 2024
Cash flows from operating activities:
Net loss	(1,548)^†	(10,848)	2,523^†	(40,365)^†
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	3,555^†	3,559	3,602^†	3,504^†
Intangible assets impairment	—	—	0^†	0^†
Share-based compensation	1,932^†	5,565	13,957^†	18,843^†
Payment-in-kind “PIK” interest	4,581^†	4,371	4,296^†	12,709^†
Deferred income taxes	—	—	0^†	0^†
Gain on troubled debt restructuring	0^†	0	0^†	0^†
Net accretion of investments	(21)^†	(181)	(25)^†	(132)^†
Loss on disposal of property, equipment, and capitalized software	0^†	87	114^†	0^†
Other, net	536^†	493	5,452^†	152^†
Changes in assets and liabilities, net of acquired assets and liabilities:
Accounts receivable	(11,358)^†	(5,122)	8,390^†	(5,519)^†
ACO REACH performance year receivable	146,750^†	(373,271)	—	164,302^†
Other assets	9,687^†	(120)	(5,606)^†	3,333^†
Medical cost payable	(15,926)^†	(15,495)	(5,916)^†	(13,340)^†
Risk adjustment payable	0^†	(4,996)	—	(12,073)^†
Accounts payable and other liabilities	(7,563)^†	(4,920)	244^†	10,202^†
Unearned revenue	0^†	0	97^†	(7)^†
Warrant liability	562^†	(2,649)	—	460^†
ACO Reach performance year obligation	(134,013)^†	382,478	—	(163,744)^†
Net cash used in operating activities	(2,826)^†	(21,049)	(24,394)^†	(21,675)^†
Cash flows from investing activities:
Purchases of investments	(7,029)^†	(1,195)	(2,198)^†	(3,221)^†
Proceeds from sales, paydowns, and maturities of investments	130^†	4,258	653^†	3,835^†
Purchases of property and equipment	(1,627)^†	(1,026)	(791)^†	(665)^†
Proceeds from sale of business, net	0^†	61,139	0^†	0^†
Net cash provided by investing activities	(8,526)^†	63,176	(2,336)^†	(51)^†
Cash flows from financing activities:
Proceeds from issuance of common stock	—	—	—	0^†
Proceeds from long-term borrowings	—	—	77,671^†	(10,278)^†
Proceeds from short-term borrowings	—	—	2,000^†	—
Repayments of short-term borrowings	0^†	(1,000)	0^†	0^†
Distributions to noncontrolling interest holders	(547)^†	(1,702)	1^†	(3,041)^†
Net cash used in financing activities	(547)^†	(2,702)	(14,278)^†	(13,319)^†
Net increase (decrease) in cash and cash equivalents	(11,899)^†	39,425	(41,008)^†	(35,045)^†
Cash and cash equivalents of total operations – beginning of year	224,830	185,405	226,413	261,458
Cash and cash equivalents of total operations – end of period	212,931	224,830	185,405	226,413
Supplemental disclosures of cash flow information:
Unamortized discount on long-term borrowings	—	—	—	(23)^†
Unamortized deferred financing costs	—	—	—	1,179^†
Cash paid for interest	—	—	—	1,267^†
Issuance of equity warrants	—	—	—	0^†
Changes in unrealized gain on available-for-sale securities in OCI	0^†	0	0^†	0^†

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.